New-Generation Weight-Loss Drugs
Kartavya Desk Staff
Source: TH
Context: A recent U.S. study published in the journal Obesity reveals that new weight-loss drugs like semaglutide and tirzepatide show reduced effectiveness in real-world settings compared to clinical trials.
About New-Generation Weight-Loss Drugs:
• What are They? Injectable GLP-1 receptor agonists originally developed to manage Type 2 diabetes, now repurposed for chronic weight management.
• Injectable GLP-1 receptor agonists originally developed to manage Type 2 diabetes, now repurposed for chronic weight management.
• Key Drugs: Semaglutide (branded as Ozempic/Wegovy) – developed by Novo Nordisk Tirzepatide (branded as Mounjaro/Zepbound) – developed by Eli Lilly
• Semaglutide (branded as Ozempic/Wegovy) – developed by Novo Nordisk
• Tirzepatide (branded as Mounjaro/Zepbound) – developed by Eli Lilly
• Features: Mimic the action of GLP-1 (glucagon-like peptide-1) to suppress appetite and slow digestion. Shown to cause 10-15% body weight loss in controlled clinical trials. Approved by US FDA also recently introduced in India for obesity management.
• Mimic the action of GLP-1 (glucagon-like peptide-1) to suppress appetite and slow digestion.
• Shown to cause 10-15% body weight loss in controlled clinical trials.
• Approved by US FDA also recently introduced in India for obesity management.
• Limitations: Low adherence in real life: Many patients discontinue treatment early or reduce dosage due to cost, side effects, or lack of follow-up. Economic constraints: High cost of GLP-1 drugs limits long-term use, especially in developing countries like India where out-of-pocket expenditure is high. Dependency for sustained impact: Weight regains occurs quickly after discontinuation, making long-term adherence essential for benefit.
• Low adherence in real life: Many patients discontinue treatment early or reduce dosage due to cost, side effects, or lack of follow-up.
• Economic constraints: High cost of GLP-1 drugs limits long-term use, especially in developing countries like India where out-of-pocket expenditure is high.
• Dependency for sustained impact: Weight regains occurs quickly after discontinuation, making long-term adherence essential for benefit.